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1. Introduction 
Neuroendocrine neoplasms (NENs) are a group of tumors originating from the neuroendocrine 
system. NENs develop most commonly in the gastroenteropancreatic (GEP) tract [1, 2]. Despite the 
seven-fold increase in NEN incidence in the last four decades, no clear risk factors have been 
recognized for these tumors. Research over the last decades has underlined the dual role of 
inflammation in the development and progression of malignancies. Chronic and unbalanced 
inflammation enhances tumorigenesis. This relationship could be hypothesized also in GEP NEN 
development, as chronic inflammatory diseases and chronic gastritis are well known predisposing 
conditions for these tumors. However, under specific inflammatory conditions, immune cells are 
able to eliminate dysplastic and cancer cells. In this review, we provide an overview concerning the 
complex interplay between inflammation and GEP NENs, focusing on the tumorigenesis and 
clinical implications in these tumors.  
 
 
2. Role of microenvironment in tumorigenesis and progression of GEP NENs 
through modulation of inflammation 
The tumor microenvironment (TME) is a dynamic compartment that develops during cancer 
evolution. TME is not simply constituted by neoplastic cells, but it includes blood and lymphatic 
vascular networks, extracellular matrix, cancer-associated fibroblasts (CAFs), adipose cells, 
neuroendocrine cells, immune-inflammatory cells and different molecular players, such as pro-
inflammatory and oncogenic mediators [3]. The interplay between all these elements, in particular 
the inflammatory microenvironment, is crucial to shape the fate and the evolution of several tumors 
(figure 1). Although underestimated until now, TME has a relevant role in tumorigenesis, 
progression and response to the therapy in GEP NENs [4, 5].  
 
2.1 Vasculature 
Blood and lymphatic vessels deliver nutrients and oxygen, necessary for cancer survival, and are 
relevant for tumor progression and the development of immune cell infiltration. The hypoxic tumor 
microenvironment prompts the release of proangiogenic factors, like vascular endothelial growth 
factor (VEGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF) and 
transforming growth factor β (TGF-β), promoting the rapid and aberrant vasculature formation 
within the tumor [6]. NENs are highly vascularized. The development of new blood vessels 
involves different proangiogenic factors. The best known and characterized is surely VEGF and its 
receptors (VEGFRs). VEGF overexpression is generally associated to an increased microvascular 
density, leading to tumor progression. GEP NENs are characterized by a marked expression of 
VEGF/VEGFRs [7, 8], but the relationship between VEGF, tumor vascularization and prognosis is 
not straightforward. In gastrointestinal NENs this correlation is unclear, only in pancreatic NENs it 
has been reported that VEGF expression is higher in benign and low-grade tumors. Therefore, this 
condition results to be associated to a good prognosis and prolonged survival [9, 10]. A 
comprehensive explanation for this paradox could be that in pancreatic NENs the vascular density is 
more likely a marker of differentiation than a marker of aggressiveness. FGF, PDGF and TGF-β are 
also strongly expressed in GEP-NENs [4].  
In order to study in vivo the tumor-induced angiogenesis, we have developed an innovative model 
through the xenograft of human NEN cells into Tg(fli1a:EGFP)
y1
 [11] zebrafish embryos. This 
transgenic line, expressing the enhanced green fluorescent protein (EGFP) in the endothelial cells of 
the entire vascular tree, offers the possibility to estimate the proangiogenic potential of injected 
tumor cells and to analyze the contribution of the TME to the tumor progression in a living selective 
microenvironment [12-14]. 
 
2.2 Reactive stromal cells 
Extracellular matrix is structurally constituted by interstitial matrix, which mainly includes stromal 
cells, and by basement membrane. Extracellular matrix contains soluble molecules, such as 
chemokines, matrix metalloproteinases, protease inhibitors and growth factors. An abnormal 
extracellular matrix favors tumor progression, promoting cellular transformation and metastasis 
[15]. Among different factors involved in extracellular matrix remodeling, proteoglycans play 
different roles in cancer. In GEP NENs the expression of syndecan 2 and glypican 1 proteoglycans 
has been reported to be high in well-differentiated tumors. Their levels correlated positively with 
patient survival [16]. In a recent paper, the prometastatic enzyme heparanase, a glucuronidase, 
resulted to be overexpressed in well- but not in poorly differentiated NENs [17]. 
CAFs, a population of activated fibroblasts (also known as myofibroblasts), represent the major 
non-cancer cells within the tumor stroma. They share properties with fibroblast stimulated by 
inflammation or wound healing. Indeed, they can secrete a variety of mesenchyme-specific proteins 
[18], chemokines (CXCL-8 and CXCL-12), cytokines (interleukin-6) and growth factors, including 
VEGF, TGF-β, FGF, hepatocyte growth factor and epidermal growth factor (EGF). These factors 
are involved in paracrine signaling or activate CAFs in autocrine loops. The crosstalk between 
CAFs and cancer cells is responsible for the promotion and maintaining of the activated phenotype 
of fibroblasts and, in turn, the production of soluble factors by CAFs fosters the cancer growth and 
progression, promoting the remodeling of extracellular matrix, cell proliferation and angiogenesis 
[19]. Activated fibroblasts are recruited to the tumor site miming excessive fibrosis, as a 
consequence of inflammation and aging [20]. It has been observed that NENs are often associated 
with local or distant fibrosis and that the crosstalk between NEN cells and fibroblasts has a pivotal 
role in fibrogenesis [21]. The most common examples of fibrosis are mesenteric fibrosis, associated 
with small bowel NENs in up to 50% of cases [22], and carcinoid heart disease, characterized by 
development of fibrotic endocardial plaques, that affects up to 40% of patients with carcinoid 
syndrome [23, 24]. Several factors take part in NEN-related fibrogenesis, such as serotonin, 
connective tissue growth factor, PDGF, insulin-like growth factors (IGFs), FGF and VEGF [21]. A 
strict interaction between NEN cells and fibroblasts, with a mutual induction of cell proliferation, is 
relevant for these events [4]. 
The TME exerts a significant role in every step of tumorigenesis and progression through reciprocal 
interactions and modulation of chronic inflammation [25]. It is well-known the dual role of immune 
infiltration in tumors [26]. An imbalance of the immune system may cause chronic inflammation 
with a pro-oncogenic environment, on the contrary a well-regulated adaptive immune response is 
considered anti-tumorigenic [27]. Immune surveillance can eliminate some pre-malignant lesions 
[28], but over time, tumor cells can undergo a process called immune editing [29], becoming 
resistant to the first line of defense and able to manipulate immune cells through secretion of 
chemokine and cytokines [26]. Therefore, an inflammatory response may be either pro- or anti-
tumorigenic, depending on the overall balance of inflammatory mediators and on the type of 
immune cells infiltrating the tumor. These aspects have been also reported in GEP-NENs, where 
chronic inflammation is a relevant hallmark [1]. 
Tumor-infiltrating immune cells include T and B lymphocytes, natural killer (NK) cells, 
macrophages, dendritic cells (DC) and neutrophils [30, 31]. In a contest of chronic inflammation, 
leukocytes provide directly and indirectly several factors that can promote proliferation of cancer 
and stromal cells [32], stimulate angiogenesis, facilitate cancer cell dissemination and tumor 
immune evasion [33].  
Tumor-infiltrating lymphocytes contain various proportions of T helper cells (CD4+) and cytotoxic 
T cells (CD8+). Their presence is associated with a better prognosis in a wide range of solid tumors 
[25, 30, 34]. In NENs, particularly in carcinoids of lung and midgut, tumor-infiltrating lymphocytes 
(CD4+, CD8+ and CD20+) are often found and its occurrence correlates inversely with the presence 
of metastases [35]. Also pancreatic NENs commonly showed an intratumoral infiltration with 
CD4+, CD8+ and CD3+ T cells [36]. A recent paper characterized T-cell subpopulations in both 
intra- and extra-tumoral compartments in small intestine and pancreatic NENs through a panel of T-
cell markers, comprising CD3 (general T-cell marker), CD45RO (T memory), CD8 (cytotoxic T 
cell), and FOXP3 (T regulatory cell). T-cells (CD3+, CD45RO+ and CD8+) were observed in both 
small intestine and pancreatic NENs, with a more relevant infiltration in pancreatic NENs, 
particularly in the extratumoral compartment. Levels of FOXP3 T regulatory cell infiltration were 
low in both tumors [37]. However, the expression of regulatory T cells appears to be not marginal 
in NENs, particularly in aggressive forms. These cells can stimulate metastasis formation and 
mediate the suppression of the immune system [38-40]. In another series of NENs, pancreatic 
intratumoral regulatory T cell infiltration was present in 55% of intermediate/high-grade tumors, 
whereas only in 16% of low-grade NENs [39]. Patients with midgut carcinoid showed higher levels 
of circulating regulatory T cells compared to healthy donors, particularly in patients with a high 
tumor burden [40].  
Macrophages represent a remarkable portion in tumor mass. These cells display a substantial grade 
of plasticity, with different state of activation in response to a variety of external stimuli. Indeed, 
macrophages can be polarized into type I (M1) and type II (M2) [41]. M1 macrophages exert an 
anti-tumor effect, through the production of several pro-inflammatory cytokines, chemokines, and 
effector molecules, such as interleukin-1 (IL-1), IL-12, IL-23, TNF-, CXCL10, iNOS and 
MHCI/II. In contrast, M2 macrophages promote tumor proliferation and progression, tumor 
angiogenesis, metastasis formation and immune suppression, through the expression of a wide 
spectrum of anti-inflammatory molecules, such as IL-10, TGF-β and arginase-1 [41, 42]. M2 
macrophages can also switch T-lymphocytes to regulatory T cells, allowing the suppression of 
tumor immunity [43]. Numerous studies have demonstrated in most human cancers that a high 
presence of infiltrated macrophages is linked with poor prognosis [26, 44]. In pancreatic NENs, 
tumor-associated macrophages infiltration correlates with proliferative activity, tumor grade, 
presence of liver metastases, angiogenesis and recurrence after surgery [45-47]. In addition, low 
tumor-associated macrophages, low peritumoral CD4+ cell and high intratumoral CD8+ T cell 
infiltration was associated with prolonged disease-free and/or disease-specific survival in pancreatic 
NENs [48]. 
DCs are key mediators of the adaptive and innate immune responses, therefore, these cells play a 
pivotal role in shaping the immune response. DCs are designed to present antigens and provide 
different signals, such as co-stimulatory molecules and cytokines, essential for T cell activation, to 
interact with other immune cells, including NK and B cells [49]. Tumor-infiltrating DCs are present 
in different types of solid tumors and can be associated with both a better and poor prognosis [50]. 
Besides, phenotype and amount of DCs are dynamic over time and may considerably influence 
tumor progression [49]. Although a complete characterization of DCs has never been reported in 
GEP NENs, Schott et al. described that vaccination with tumor lysate-pulsed DCs induced a clear 
antitumor effect in a patient with pancreatic neuroendocrine carcinoma [51]. Interestingly, 
Papewalis and colleagues identified a population of DCs with NK cell properties, expressing the 
CD56 NK marker [52]. Afterwards, it has been reported higher numbers of circulating  
CD14+/CD56+ monocytes in 4 patients with gastrointestinal neuroendocrine cancer compared to 
healthy controls [53]. 
NK cells are a subset of innate lymphoid cells and represent about 5–15% of the circulating blood 
mononuclear cell population. These cells are involved in the first line of defense against infection 
and cancer [54, 55]. It has been reported that NK cell activity, expressed as percentage of 
cytotoxicity in patients with gastrointestinal NENs, is affected by the type of gastrointestinal 
hormones produced and by the course of the disease with an impairment during tumor progression 
[56]. In addition, serotonin, the hormone most frequently related to carcinoid syndrome in NENs, 
stimulates migration of NK cell [57] and protects these cells against oxidatively induced functional 
inhibition and apoptosis [58]. 
 
2.3 Inflammatory mediators 
The interplay between immune cell components and tumor cells is well orchestrated and several 
molecular mediators and pathways take part in inflammation-mediated cancer and immune 
modulation. Common inflammatory mediators are cytokines, chemokines, nuclear factor kappa B 
(NFk-B), STAT3, cyclooxygenase-2 and reactive oxygen and nitrogen species. An inflammatory 
stimulus causes the recruitment and activation of different immune cells (macrophages, DCs and 
neutrophils), which release reactive oxygen and nitrogen species. The over-production of these 
oxidative agents causes genomic instability, the increase of angiogenesis and transcriptional 
activation of proto-oncogenes, concurring to inflammation-induced carcinogenesis and tumor 
metastatic potential [59].  
Chronic inflammation plays a critical role in the occurrence of GEP NENs through the network of 
different cytokines and growth factors, which modulate tumor cell growth [60], such as TNF-α, IL-
2, IL-6, IL-8, IL-1β [61-65]. Noteworthy, cytokine genes are highly polymorphic. Single nucleotide 
polymorphisms affect cytokine expression and function regulation. IL-2–330G/G genotype was 
associated to higher IL-2 serum levels and an higher risk to develop GEP NENs compared to 
healthy volunteers. Interestingly, highest IL-2 serum levels were observed in patients with 
functional NENs [61]. Similar associations have been observed between IL-6–174G/G, TNF-α-
1031C and IL-1β-511C/T genotypes, high circulating levels of corresponding cytokines and an 
increased risk to develop GEP NENs [62, 66, 67]. GEP NENs are characterized by an abundant 
production and secretion of growth factors, in particular VEGF, EGF, PDGF, IGF, FGF and TGF-β, 
which, in combination with high level of cytokines, connect chronic inflammation to 
gastrointestinal carcinogenesis [68-71].  
The pro-inflammatory mediators, produced during chronic inflammation, activate several signaling 
cascades, such as NFk-B and STAT3 pathways, that are central in the development and maintaining 
of the TME. NFk-B is a transcription factor that, following an inflammatory stimulus, translocates 
to the nucleus, where it activates transcription of target genes encoding pro-inflammatory cytokines, 
chemokines, NOS2 and cyclooxygenase-2. Moreover, NFk-B activation stimulates angiogenesis by 
VEGF secretion and makes tumor cells more resistant to necrosis and apoptosis. NFk-B is linked to 
different cellular signaling pathways. Over the last years, several reports have described Notch-
NFk-B pathway crosstalk [72]. In NENs it has been demonstrated that non-canonical Notch 
signaling impacts on tumorigenesis by the involvement of different signaling pathways, among 
them NFk-B [72, 73]. 
The signal transducer and activator of transcription, STAT3, has a relevant role in inducing and 
maintaining a pro-carcinogenic inflammatory TME. Its persistent activation in cancer cells 
promotes cell proliferation, tumor invasion and angiogenesis. Like NFk-B, STAT3 is activated by 
different factors and it can stimulate the transcription of several pro-inflammatory cytokines, 
controlling inflammation and immune evasion. In GEP NENs STAT3 has been reported to be up-
regulated and nuclear STAT3 expression correlated with metastatic status [74]. 
Other players taking part in this complex scenario, are cyclooxygenases. These are enzymes 
necessary to the production of prostaglandins from fatty acids. Prostaglandins are key mediators in 
inflammation, and in tumors can affect cell proliferation, DNA mutation rates, angiogenesis and 
promote metastasis formation [75]. Cyclooxygenase-2 expression has been detected in the vast 
majority of GEP NENs, both in functioning and non-functioning tumors [76], and its expression has 
been associated with a poor prognosis and more aggressive pathologic variables [77-79].  
Therefore, chronic inflammation promotes tumor, causing genomic instability, increasing 
angiogenesis, altering the genetic/epigenetic state and increasing cell proliferation. Several studies 
have shown that GEP NENs are closely associated with inflammatory conditions. 
 
 
3. NEN and inflammatory GEP diseases 
The gastrointestinal tract contains the highest concentration of bacteria anywhere within the human 
body. This organ is constantly exposed to materials originating from the external environment. The 
balance of the gastrointestinal microbial community is critical not only for this organ but also for 
maintenance of host health. Indeed, failure of gut homeostasis is an important factor in the 
pathogenesis and progression of systemic inflammation, which has a relevant role in the process of 
aging and several age-related disease [80, 81]. 
Throughout the whole gastroenteric tract and pancreas at least 19 types of neuroendocrine cells 
have been observed. As previously reported, these cells are not exempt from the detrimental effects 
of long-standing inflammation. Indeed, neuroendocrine cells can be overstimulated by chronic 
inflammation, leading to hyperplasia and sometimes to dysplasia, that may evolve to neoplastic 
transformation. This consequential relationship has been demonstrated in some districts of the GEP 
tract. 
 
3.1 Gastric NEN 
Gastric NENs are tumors originating from enterochromaffin-like (ECL) cells which are mainly 
localised in the gastric fundus and corpus. The main role of ECL-cells is the secretion of histamine, 
that stimulates acid secretion by parietal cells. Clinically, gastric NENs are categorized into types I, 
II, and III. Type I lesions correspond to the majority of gastric NENs and they are associated with 
chronic atrophic gastritis, either autoimmune-driven or as a consequence of Helicobacter pylori 
infection. In chronic atrophic gastritis, the destruction of the gastric parietal cells reduces the 
production of hydrochloric acid and intrinsic factor, promoting hypergastrinemia and pernicious 
anemia, respectively. The gastrin excess stimulates ECL cells proliferation and favors the 
development of type I gastric NEN [82, 83]. 
A population-based case-control study, comparing 1,138,390 cancer cases with 100,000 matched 
individuals without cancer, showed that subjects with chronic atrophic gastritis associated with 
pernicious anemia have a significantly increased risk of type I gastric NENs (odds ratio, 11.43; 95% 
CI 8.90–14.69) [84]. This tumor arises in patients with chronic atrophic gastritis in a percentage 
variable from 1 to 11%  [85-88]. 
Helicobacter pylori is a gram-negative bacterium whose outer membranes are composed by 
lipopolysaccharides. Experiments made on rat ECL cell preparation showed that Helicobacter 
pylori lipopolysaccharides stimulate histamine release, that was independent by the gastrin action, 
and potentiate gastrin-driven DNA synthesis in ECL cells [89]. 
Other alterations in the gastric microbiota could be also involved in this detrimental process. In fact, 
hypochlorhydria is able to modify the composition of the gastric microbiota by providing a different 
environment for colonization. This event could potentially increase the risk of developing a gastric 
malignancy. A recent study comparing the human gastric microbiota in different conditions, showed 
that autoimmune atrophic gastritis resulted in greater bacterial abundance and diversity compared to 
normal stomach and patients with Helicobacter pylori-induced atrophic gastritis. In both patients 
with atrophic gastritis due to autoimmune etiology or Helicobacter pylori, an over-activation of 
several pathways has been observed compared to controls. Interestingly, gastric-atrophy resulted to 
be associated with a modulation in the citric acid cycle, a biochemical pathway with a relevant role 
in gastric carcinogenesis [90].  
Therefore, autoimmune stimuli or Helicobacter pylori infection trigger an inflammatory response 
that determines parietal cell loss [91]. ECL cells are spared by this cellular destruction and induced 
to proliferate [89]. Indeed, in the setting of type A chronic atrophic corpus-fundus restricted 
gastritis, both hyperplastic and dysplastic lesions of ECL cells may be observed (figure 2), each 
bearing increased risk of tumor development [88]. It was shown that a gastric mucosa with severe 
hyperplasia (at least 6 intraglandular ECL cell chains of at least 5 cells each per mm of mucosa or at 
least 9 linear plus micronodular changes) and dysplasia (enlarged, fused or stroma dissected 
micronodules or microinfiltrative lesions) needs to be adequately followed by endoscopy and 
biopsies because of the increased neoplastic risk of these lesions [88]. 
 
3.2 Pancreatic NEN 
Chronic pancreatitis represents an independent significant risk factor for pancreatic cancer [92, 93]. 
The strength of the relationship between these two diseases has been widely reported. In a 
multicenter cohort study of 2015 cases [92] of pancreatitis, 56 cases of pancreatic cancer were 
registered during a mean follow-up of 7.4 years.  Among these, 29 cases were diagnosed 2 years 
after the diagnosis of pancreatitis. This number was higher than the expected for age, sex and the 
center. A case-control study [93] analyzed how frequent was the occurrence of pancreatitis in 2639 
patients with pancreatic cancer, compared to 7774 control subjects. The evidence was that 
pancreatitis was present in around 6% of patients with cancer and it represents a strong risk factor 
for development of pancreatic tumors. Although in most of these studies the tumor histotype was 
not specified, this association appears to be relevant for pancreatic adenocarcinoma.  
On the other hand, it is less clear the potential association between NEN and pancreatitis. In this 
setting, even hyperplastic and dysplastic lesions of endocrine cells consequent to inflammation, 
have never been clearly described. Rather, what is known is that, in the late phase of chronic 
pancreatitis, an apparent prominence of the endocrine cells is observed, probably due to the 
preferential loss of acinar tissue. This "pseudohypertrophy" may be difficult to distinguish from 
neuroendocrine microadenoma (figure 3). Therefore, data related to the incidence of cancer in this 
setting may be influenced by the potential of incorrect diagnosis of NEN.  
A case-control study including 162 sporadic pancreatic NENs and 648 controls showed that history 
of chronic pancreatitis (OR =  8.6; 95% CI, 1.4–51) and diabetes (OR =  40.1; 95%  CI, 4.8–328.9) 
resulted to be independent risk factors for the development of this tumor [94]. Although the 
association between pancreatic NENs and chronic pancreatitis has been not confirmed in other 
studies, a recent meta-analysis showed that history of diabetes mellitus was associated with an 
increased risk of sporadic pancreatic NENs (pooled adjusted odds ratio 2.74, 95% CI: 1.63-4.62) 
[95]. It is still unclear whether diabetes is a real risk factor or a secondary effect due to the 
pancreatic tumor. Furthermore, it is possible that chronic inflammation and oxidative stress may 
contribute to the pathogenesis of both diabetes and pancreatic NENs through the induction of DNA 
mutation [96]. A recent study showed that in genetically engineered transgenic mice, chronic 
inflammation in the absence of TP53 developed in all animals several subtypes of pancreatic 
cancer, including NENs [97].  
 
3.3 Small bowel and appendix NEN 
Several chronic inflammatory bowel conditions represent a potential risk factor predisposing to the 
development of small bowel NENs [98]. 
In celiac disease (CD), an immune-mediated disorder involving the small bowel, serotonin-
producing neuroendocrine cells are increased [99]. Well-oriented bioptic samples taken from 17 
patients affected by refractory CD, were compared with 84 non-healthy and 16 healthy control 
subjects. In this study the number of neuroendocrine cells was absolutely more represented in 
refractory CD. A higher expression was also observed in case of CD before gluten-free diet that 
restored to normality after [99]. This finding was indicative of a possible etiologic role of the 
immune system in the proliferative activity of these cells [100]. In addition, significantly higher 
serotonin levels have been described in patients with CD compared to healthy subjects [101]. In a 
large population-based cohort study, the standardized incidence ratio for small-intestinal cancer 
(adenocarcinomas, stromal tumors and NENs) was more than fourfold in patients with CD. 
However, the association between CD and NENs is doubtful. Indeed, in this study there are no data 
on the number of patients with NENs [102]. Despite the hyperplasia of entero-chromaffin cells has 
been demonstrated in CD, only few case reports have been published describing CD subjects with 
small bowel NENs [103-107]. 
Population-based studies [108, 109] have shown that the incidence of NENs is significantly 
increased in inflammatory bowel diseases (IBD) involving the small bowel. Among a cohort of 
20.917 patients affected by Crohn's disease in the time frame between 1978 and 2010, 23 small 
bowel adenocarcinoma and 9 NENs were observed, resulting, respectively in a 14-fold and 7-fold 
increased neoplastic risk, as compared to the general population. In both histotypes the severity of 
the surrounding inflammatory disease was moderate to severe and its distribution was extensive. 
Furthermore, while almost all adenocarcinomas arose in mucosal areas affected by Crohn's disease, 
78% of NENs developed far from them. This suggests that the development of NENs may be 
secondary to the effects of pro-inflammatory cytokines, rather than a local inflammatory effect from 
adjacent Crohn's disease. In the same study 42.872 cases of ulcerative colitis were also analyzed 
and no significantly increased risk of cancer was found among those patients [108]. 
The appendix is the third more frequent site of gastrointestinal-NENs. Appendiceal NENs are often 
diagnosed incidentally on histopathological examination of appendectomy specimens. In about two 
thirds of cases, they are found at the tip of the organ and are not the direct cause of the appendicitis 
[110]. In case of acute appendicitis, the number of enterochromaffin cells, that populate the crypt 
epithelium, and of subepithelial neuroendocrine cells is depleted [111]. Although no clear data are 
available concerning a potential association between chronic appendiceal inflammation and risk of 
NEN, the inflammation caused by other disease, such as Crohn’s disease, represents a favorable 
situation for the development of the appendiceal NEN. Indeed, it seems to occur more frequently in 
the samples from inflamed surrounding than that reported in autopsy studies [112]. 
A recent meta-analysis of observational studies provides additional evidence for a link between 
inflammation and intestinal NENs. This study reported that aspirin use was associated with a 
significant decrease in the risk of several tumors, including small intestinal NENs (RR = 0.17, 95% 
CI: 0.05–0.58) [113].  
 
3.4 Colonic and rectal NEN 
During inflammatory diseases affecting the colonic and rectal tube, as IBD, post-dysenteric colitis, 
Campylobacter enteritis and irritable bowel syndrome, an increase in number of neuroendocrine 
cells (figure 4) can be observed [114]. In all these cases, there is a disruption of the intestinal 
epithelial barrier that dysregulates innate and immune responses toward the enteric microbiota. This 
favors the release of several cytokines, that finally affect the commitment of multipotential-
secretory precursor cells and promote the differentiation of enteroendocrine precursor cells [115]. 
This phenomenon was deepened with in vitro and in vivo models of intestinal inflammation [114], 
where it was shown that PI3K/Akt signaling and autophagy are implicated in the increase of colonic 
intestinal epithelial cells expressing chromogranin. Indeed, the concomitant treatment of interferon-
γ plus TNF-α increased the number of chromogranin A-positive cells in the distal colon of colitic 
mice and this determined an increase of pAkt (Ser473) and pAkt(Thr308), an augmented 
phosphorylation of β-catenin at Ser552 [116], GSK3β at Ser9 [117] and 14-3-3ζ at Ser58 [118], 
three well-known targets of Akt, and enhanced PTEN phosphorylation. p-PTEN is the inactive 
form, that causes PI3K/Akt signaling activation in chromogranin A-positive cells. The reason why 
cytosolic chromogranin A increases in case of inflammation is not clear. It was supposed that 
entero-endocrine cells, with their capacity of antigen internalization, could represent a relevant 
sensor for the mucosa during inflammation. Similarly, in humans neuroendocrine differentiation is 
relatively common and represents an early event in the ulcerative-colitis-associated carcinogenesis, 
where chromogranin A and p53 are up-regulated [119]. 
Discordant opinions exist on whether the coexistence of IBD (both ulcerative colitis and Crohn's 
disease) and colonic and rectal NEN is only coincidental. According to some authors [120], an 
apparent high rate of incidental NENs in IBD patients could be explained only because they 
frequently undergo intestinal surgery. Indeed, adjusted for resection type, sex and age, a lower 
prevalence of NENs in IBD patients has been reported compared to non-IBD patients (diverticulitis 
or ischemic). 
Other studies reported an increased risk (up to 15 times) of intestinal NENs in IBD. While 
neuroendocrine tumors are more common in segments that are free from inflammation [121, 122], 
neuroendocrine carcinomas develop mainly in inflamed mucosa [122, 123], just like what it 
happens for non-neuroendocrine cancer. Although NENs occur in ulcerative colitis [124] as well as 
during Crohn's disease, some authors are inclined to think that the incidence is higher in Crohn's 
disease, triggered by prolonged inflammation, even in distant bowel segments [121, 125].  
 
 
4. Prognostic value of inflammatory markers in NENs 
In support of a role of inflammation in tumor development and progression, several studies 
recognized few inflammatory biomarkers as independent prognostic markers in patients with 
tumors [126]. Most of these data have been recently confirmed in NENs. Neutrophils, the most 
abundant white blood cell subset, appear to have an active role in tumorigenesis and tumor 
progression by secreting several cytokines, able to promote tumor cell proliferation, local invasion, 
angiogenesis and resistance to chemotherapy [127]. On the other hand lymphocytes play an 
important role in cell-mediated immune response activation. CD4+ T lymphocytes are involved in 
senescence and cancer immune-surveillance, detecting and eradicating precancerous and cancerous 
cells, also by activation of CD8+ T lymphocytes. Lymphocyte infiltration is common in NENs, as 
assessed by immunohistochemistry for CD3, CD4, CD8, and CD56 [39, 128]. In patients with 
intermediate-grade NENs a prominent tumor infiltration of T cells (CD3+) was associated with 
improved regression free survival, while a low level of infiltrating regulatory T cells in liver 
metastases was a predictor of prolonged survival [39]. 
Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are systemic 
inflammation markers with a prognostic value in several neoplasms. Some studies addressed the 
prognostic relevance of NLR and PLR in GEP NENs, demonstrating that these parameters could be 
useful in identifying patients with a worse outcome [129, 130]. In a retrospective study including 
172 patients with pancreatic NENs, elevated NLR and PLR were both associated with advanced 
tumor stage and high grade. In the univariate analysis, elevated NLR and PLR were both 
significantly associated with decreased overall survival and disease free survival, while in the 
multivariate analysis, the preoperative NLR, but not the PLR, was an independent risk factor. In 
detail, a preoperative NLR >2.31 was predictive of significantly worse survival in the subgroup of 
patients with stage I/II or grade 1/2 tumors. Moreover, predictive models based on both the NLR 
and conventional stratification systems, such as the WHO classification and AJCC stage, showed 
improved predictive power as compared to the stratification systems alone [131].  
Recently, increased NLR was found to be associated to advanced T stage, lymph node metastasis, 
tumor thrombus formation and advanced grade in pancreatic NENs. In addition, the recurrence-free 
survival of these patients with high NLR was significantly lower compared with those with low 
NLR [132]. Accordingly, in patients with gastric NEN, NLR was an independent prognostic factor 
for recurrence-free survival and overall survival [133].  
The gamma-glutamyltransferase (GGT) level is a biomarker of oxidative stress and correlates with 
inflammation in the extracellular tissue microenvironment. GGT can play a relevant role in cancer 
progression and biological behaviour, and is considered a significant prognostic biomarker in 
several tumors. On the other hand, lymphocytopenia, indicating a state of depressed immune 
function, could negatively affect survival of cancer patients because of a reduced host response. 
Therefore, the GGT to lymphocyte ratio index (GLRI) could represent a potentially useful 
prognostic biomarker in oncology. In a retrospective study including 125 non-functioning 
pancreatic NENs undergoing curative resection, GLRI was found to be an independent predictor of 
overall survival and disease free survival. Moreover, preoperative GLRI was associated with 
advanced tumor stage [134]. 
C reactive protein (CRP) is an acute-phase protein, produced in the liver, whose synthesis is 
triggered by secretion of IL-6 from macrophages and T cells. Any type of chronic or acute 
inflammatory process can activate acute phase response, making CRP levels a sensitive but 
unspecific marker. CRP has been shown to be an independent prognostic marker in patients with 
secreting (insulinoma, gastrinoma and other rare functioning tumours) and non-secreting sporadic 
pancreatic NENs, since it correlated with overall survival. Moreover in univariate Cox regression, 
pancreatic NEN patients with elevated CRP levels had a significantly higher hazard ratio for death 
[135]. 
Angiopoietins (Ang)-1 and -2, and the tyrosine kinase receptor Tie-2 family are involved in 
angiogenesis that in turn is known to have a key function in tumorigenesis. In addition, this system 
has a relevant role in the inflammatory processes, with a close loop relationship between 
angiogenesis and inflammation, particularly in IBD. Interaction of Ang-1 with Tie-2 promotes 
endothelial cell survival, while Ang-2 exerts a marked pro-angiogenic effect, when VEGF is 
present, and is involved in chemo-attraction of monocytes in neoplastic tissue. Monocytes 
expressing Tie-2 and recruited into inflamed or neoplastic tissues can promote angiogenesis. 
Moreover, there is a soluble form of Tie-2 that has been found increased in several conditions 
including cancer. GEP NEN patients showed enhanced serum levels of soluble form of Tie-2, Ang-
1, and Ang-2, compared to age-matched healthy controls. Soluble Tie-2 and Ang-2 levels were 
significantly higher in GEP NENs with metastases compared to those without metastases. 
Furthermore, Ang-1, Ang-2, and Tie-2 expression was found to be increased in freshly isolated 
tumor cells from GEP NEN. Interestingly, an enhanced expression and function of Tie-2 was 
detected in monocytes from GEP NEN patients. Overall these data would suggest that the Ang/Tie-
2 system is involved in the growth and dissemination of GEP NENs, also favouring the recruitment 
of Tie-2(+) monocytes to the tumor site, where they can promote inflammation and angiogenesis 
[136]. Similarly, Srirajaskanthan R et al. found Ang-2 levels to be increased in patients with well or 
moderately differentiated NENs, mostly of pancreatic, duodenal or jejunum origin, as compared to 
healthy controls, and to be significantly higher in presence of metastases as compared to non-
disseminated tumours. Moreover patients with higher Ang-2 levels (>4756  pg/ml) showed a shorter 
time to disease progression, overall suggesting a potential prognostic role for Ang-2 in patients with 
NENs [137]. 
 
 
5. Therapeutic applications with new checkpoint inhibitors 
Unravelling and understanding the mechanisms implicated in the immune response to neoplasms, 
induced by tumour-associated antigens, is crucial also in the context of NENs, for gaining new 
knowledge on tumour biology and for improving the management with the perspective of an 
immunotherapeutic approach. The therapeutic implications of the involvement of immune system in 
patients with NENs are known since the introduction of interferon-α biotherapy, which inhibits cell 
cycle progression and hormone synthesis in tumor cells, reduces neoangiogenesis, and activates 
immune cells [138]. Somatostatin receptors, which are targets widely used for the diagnosis and 
therapy of NETs [139-142], are also present in immune cells and able to mediate immune and 
inflammatory reactions [143]. Monocyte-derived cells and mature T-lymphocytes express 
somatostatin receptors -2 and -3, respectively. Human lymphoid follicle centers, thymus, and spleen 
express both receptors as well. In thymus, several evidences suggest the potential physiological role 
of somatostatin receptors in thymocytes maturation [144]. Although the effects of somatostatin 
analogues on immune system are not well defined in patients with NETs, these compounds are able 
to potentiate the cytotoxicity of interleukin-2 activated peripheral blood mononuclear cells in 
patients with medullary thyroid cancer [145].   
The occurrence of immune response to NENs is demonstrated by the frequent finding of 
lymphocyte infiltration within the tumour, as discussed in the previous paragraphs. In the view of a 
potential immunotherapy, specific tumour-associated antigens recognised by CD8+ T cells have 
been identified in patients with midgut NENs [128].  
NENs can elude immunosurveillance regardless of the immunocompetence of the host. In 
pancreatic NENs, HLA class I antigen expression was lost or reduced in most of the cases, with the 
loss of beta-2microglobulin as the most frequent alteration in HLA class I phenotype. HLA class II 
antigens seemed not to contribute to the biology of NENs, since they were not expressed in all 
investigated samples [36]. However, in another study, MHC class II expression on pancreatic tumor 
cells correlated significantly with severity and activity of intratumoral inflammation, as well as with 
the infiltration of CD4+ T lymphocytes [146].  
Anti-tumor immune responses can be impaired by regulatory T cells. Midgut carcinoid patients 
exhibited increased frequencies of circulating regulatory T cells and patients’ T cells were less 
responsive to polyclonal activation and had a decreased proliferative capacity compared to controls. 
Moreover, circulating T helper-promoting cytokines were reduced [40]. 
Programmed death 1 (PD-1), its ligands (PD-L1 and PD-L2) and cytotoxic T-lymphocyte antigen 4 
(CTLA-4) are immunosuppressive molecules with a relevant role in the host immune response to 
tumors, inhibiting T-cell activation. Lamarca A. et al. found that one third of 62 patients with well-
differentiated small intestinal NEN expressed PD-L1 in tumor or tumor-infiltrating lymphocytes 
[147]. Expression of PD-L1 was observed also in 14% of tumors and in 27% of tumor-associated 
immune cells in patients with poorly-differentiated neuroendocrine carcinomas of the digestive 
system [148]. In GEP NEN patients, PD-L1 expression was found significantly associated with a 
high-grade WHO classification (G3) but not with gender, primary site, or lymph node status. 
Moreover, G3 tumors were characterized by strong PD-L1 expression in intra/peri-tumoral 
infiltrating immune cells [149]. Likewise, in a study of 32 metastatic GEP NEN, the expression of 
PD-L1, observed in 22% of patients, was associated with higher WHO tumor grade (grade 3) and 
had both predictive and prognostic value for survival of patients [150]. In 244 GEP NENs, mostly 
of the small intestine and pancreas and predominantly G1-G2, high tumor-infiltrating lymphocytes 
(19.6%) and high PD-1 (16.1%) expression significantly correlated with shorter patient survival and 
with a higher grading. In the same study, expression of PD-L1 (8.7%) showed a trend toward a 
shorter patient survival [151]. Furthermore, Sampedro Nunez et al. found PD-1/PD-L1 expressed in 
1 to 8% of GEP NENs. In the same patients, PD-1 tumor expression was higher in metastatic 
patients, while PD-1 expression in peripheral blood monocytes was associated with tumor 
progression [152].  
Conversely, in 66 patients with GEP NEN, mostly of pancreatic origin, PD-L1 expression was 
observed in 9%, while PD-L2 was present in 50% with no association with disease stage at 
diagnosis or survival. However, they found an inverse relationship between hypoxia and 
angiogenesis biomarkers and PD ligands, as PD-L1 positive tumors had lower VEGF-A, Hif-1a and 
Carbonic Anhydrase (CaIX) expression, while PD-L2 positive tumours had lower CaIX and lower 
proportion of vascular invasion [153]. Recently, in 102 NENs of duodenum, jejunum and ileum, 
expression of PD-L1 in ≥1% and ≥50% of tumor cells was found in 39% and 14% of cases 
respectively, with an intratumor host immune response found to be apparently absent in 34% and 
intense in 21% of cases. PD-L1 expression and extent of immune infiltration were significantly 
higher in duodenal as compared with jejunal/ileal NENs.  However, neither PD-L1 expression nor 
the degree of immune infiltration showed any prognostic significance [154]. 
Antibodies targeting PD-1 (pembrolizumab, nivolumab, PDR001, JS001), PD-L1 (avelumab, 
durvalumab) or CTLA-4 (ipilimumab, tremelimumab) have been recently used in several cancers 
with promising results, and few trials are now in progress for GEP NENs (table 1). In a phase Ib 
study (KEYNOTE-028), that included patients with various advanced solid tumors, pembrolizumab 
(10 mg/kg every 2 weeks) resulted in an objective response rate of 12% out of 25 advanced PD-L1-
positive carcinoid patients and 6% out of 16 pancreatic NEN patients. None of the carcinoid and 
pancreatic NEN patients reached complete remission, whereas 60% and 88% of the patients, 
respectively, had stable disease [155]. 
Taking into consideration that, in some studies, PD-1/PD-L1 expression appears to correlate with 
higher NEN grade and with reduced survival, immunotherapy targeting this system might be 
interesting for this subgroup of tumors with a poor prognosis. Nevertheless, more knowledge about 
the composite immune landscape of these heterogeneous tumors needs to be gained in order to 
identify the subset of NEN patients most likely to benefit from immunotherapeutic approach.  
 6. Conclusions 
Several evidences suggest a relationship between neuroendocrine system and inflammation, which 
in turn can play a relevant role in tumorigenesis. Inflammatory mediators, which are produced by 
the NEN or as part of the host innate immune response, can favour angiogenesis, cancer progression 
and metastatic spread, and can promote immune editing. On the other hand, a balanced immune 
system represents a relevant step in cancer prevention through the elimination of dysplastic and 
cancer cells. Therefore, an inflammatory response may be both pro- and anti-tumorigenic. 
Although several studies reported an increased risk of GEP NENs in patients with gastrointestinal 
inflammatory diseases (chronic atrophic gastritis, chronic pancreatitis, celiac disease, Crohn’s 
disease and ulcerative colitis), most of these studies are retrospective and characterized by potential 
biases. Therefore, further studies are required to improve the level of evidence, particularly 
concerning the association between NENs and IBD. 
The modulation of the TME may represent an innovative therapeutic strategy in G3 NENs, through 
the use of checkpoint inhibitors binding to PD-1, PD-L1 or CTLA-4, thereby preventing tumors to 
evade the immune system. This aspect will be further defined with the completion of several 
ongoing clinical trials. 
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 Figure legends: 
 
Figure 1: Components of tumor microenvironment and their role in carcinogenesis and 
tumor progression through modulation of inflammation. 
 
Figure 2: Gastric hyperplastic changes of ECL cells. (a) A mild atrophic gastritis is 
shown (hematoxylin and eosin stain, 10x magnification). (b) At higher magnification (hematoxylin 
and eosin stain, 20x magnification), few cells with a clear perinuclear halo can be observed 
(arrows). (c) They are more evident on immunohistochemistry with chromogranin (20x 
magnification): neuroendocrine cells display both linear (arrow) and micronodular arrangement (*). 
 
Figure 3: Pseudohypertophy of neuroendocrine cells in chronic pancreatitis. (a) An 
example of chronic pancreatitis, where exocrine pancreatic tissue is partially replaced by fibrosis 
(hematoxylin and eosin stain, 20x magnification). (b) Langerhans islands seem to be  hyperplastic 
and more evident on immunohistochemistry with chromogranin (20x magnification).   
 
Figure 4: Inflammatory bowel diseases and NEN. (a) The rectal submucosa was occupied 
by a neuroendocrine carcinoma (positive to chromogranin) in a patient with a history of ulcerative 
colitis of at least 20 years. In the mucosa overlying the neoplastic lesion, neuroendocrine cells were 
normally represented (20x magnification). (b) Far from this lesion, an increased number of 
neuroendocrine cells was detected (40 x magnification). 
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Table 1: Ongoing clinical trials of PD-1/PD-L1 or CTLA-4 checkpoint inhibitors in 
gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) 
 
Study Phase Drug Status Clinicaltrials.gov 
identifier 
Open-label study in patients with metastatic 
high grade NENs 
2 Pembrolizumab 
 
Recruiting NCT02939651 
Recurrent high grade neuroendocrine 
carcinoma 
2 Pembrolizumab Active NCT03190213 
Chemotherapy naïve patients with metastatic 
or unresectable high grade GEP or lung 
(excluding small cell) neuroendocrine 
carcinoma 
2 Pembrolizumab + 
cisplatin or carboplatin 
+ etoposide 
Not yet 
recruiting 
NCT03901378 
High grade neuroendocrine carcinomas 2 Pembrolizumab alone 
or Pembrolizumab + 
Irinotecan/Paclitaxel 
Recruiting NCT03136055 
Advanced GEP NENs 1/2 Pembrolizumab + 
Lanreotide depot 90mg 
Recruiting NCT03043664 
Open-label study in patients with advanced 
or metastatic, well-differentiated, non-
functional NENs of pancreatic, 
gastrointestinal, or thoracic origin or poorly-
differentiated GEP neuroendocrine 
carcinoma, that have progressed on prior 
treatment. 
2 PDR001 
 
 
 
Active NCT02955069 
Advanced NENs following failure of first-
line 
1 JS001  
 
 
Recruiting NCT03167853 
Open-label, single arm study of Nivolumab 
in combination with Ipilimumab in subjects 
with advanced NENs 
2 Nivolumab + 
Ipilimumab 
Recruiting NCT03420521 
A GCO trial exploring the efficacy and safety 
of Nivolumab monotherapy or Nivolumab 
plus Ipilimumab in pre-treated patients with 
advanced, refractory pulmonary or GEP 
poorly differentiated neuroendocrine tumors 
2 Nivolumab +/- 
Ipilimumab 
Recruiting NCT03591731 
Gastrointestinal, neuro-endocrine and 
gynaecological cancers 
2 Ipilimumab + 
Nivolumab 
Recruiting NCT02923934 
Recurrent/refractory small-cell lung cancer 
and advanced neuroendocrine tumors 
2 Nivolumab + 
Temozolomide 
Recruiting NCT03728361 
Advanced GEP and pulmonary NENs 2 Durvalumab + 
Tremelimumab 
Recruiting NCT03095274 
Unresectable/metastatic, progressive grade 2-
3 NENs 
2 Avelumab Recruiting NCT03278379 
Advanced, metastatic high grade 
neuroendocrine carcinomas (NEC G3) in 
progression after first line chemotherapy 
2 Avelumab Recruiting NCT03352934 
Unresectable/metastatic, progressive, poorly 
differentiated grade 3 neuroendocrine 
carcinomas 
1/2 Avelumab Recruiting NCT03278405 
Metastatic GEP neuroendocrine carcinoma 
(NEC G3) as second-line treatment after 
failing to etoposide+cisplatin: integration of 
genomic analysis to identify predictive 
molecular subtypes 
2 Avelumab Recruiting NCT03147404 
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Abstract 
Neuroendocrine neoplasms (NENs) are a group of tumors originating from the neuroendocrine 
system. They mainly occur in the digestive system and the respiratory tract. It is well-know a strict 
interaction between neuroendocrine system and inflammation, which can play an important role in 
NEN carcinogenesis. Inflammatory mediators, which are produced by the tumor microenvironment, 
can favor cancer induction and progression, and can promote immune editing. On the other hand, a 
balanced immune system represents a relevant step in cancer prevention through the elimination of 
dysplastic and cancer cells. Therefore, an inflammatory response may be both pro- and anti-
tumorigenic. In this review, we provide an overview concerning the complex interplay between 
inflammation and gastroenteropancreatic NENs, focusing on the tumorigenesis and clinical 
implications in these tumors. 
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1. Introduction 
Neuroendocrine neoplasms (NENs) are a group of tumors originating from the neuroendocrine 
system. NENs develop most commonly in the gastroenteropancreatic (GEP) tract [1, 2]. Despite the 
seven-fold increase in NEN incidence in the last four decades, no clear risk factors have been 
recognized for these tumors. Research over the last decades has underlined the dual role of 
inflammation in the development and progression of malignancies. Chronic and unbalanced 
inflammation enhances tumorigenesis. This relationship could be hypothesized also in GEP NEN 
development, as chronic inflammatory diseases and chronic gastritis are well known predisposing 
conditions for these tumors. However, under specific inflammatory conditions, immune cells are 
able to eliminate dysplastic and cancer cells. In this review, we provide an overview concerning the 
complex interplay between inflammation and GEP NENs, focusing on the tumorigenesis and 
clinical implications in these tumors.  
 
 
2. Role of microenvironment in tumorigenesis and progression of GEP NENs 
through modulation of inflammation 
The tumor microenvironment (TME) is a dynamic compartment that develops during cancer 
evolution. TME is not simply constituted by neoplastic cells, but it includes blood and lymphatic 
vascular networks, extracellular matrix, cancer-associated fibroblasts (CAFs), adipose cells, 
neuroendocrine cells, immune-inflammatory cells and different molecular players, such as pro-
inflammatory and oncogenic mediators [3]. The interplay between all these elements, in particular 
the inflammatory microenvironment, is crucial to shape the fate and the evolution of several tumors 
(figure 1). Although underestimated until now, TME has a relevant role in tumorigenesis, 
progression and response to the therapy in GEP NENs [4, 5].  
 
2.1 Vasculature 
Blood and lymphatic vessels deliver nutrients and oxygen, necessary for cancer survival, and are 
relevant for tumor progression and the development of immune cell infiltration. The hypoxic tumor 
microenvironment prompts the release of proangiogenic factors, like vascular endothelial growth 
factor (VEGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF) and 
transforming growth factor β (TGF-β), promoting the rapid and aberrant vasculature formation 
within the tumor [6]. NENs are highly vascularized. The development of new blood vessels 
involves different proangiogenic factors. The best known and characterized is surely VEGF and its 
receptors (VEGFRs). VEGF overexpression is generally associated to an increased microvascular 
density, leading to tumor progression. GEP NENs are characterized by a marked expression of 
VEGF/VEGFRs [7, 8], but the relationship between VEGF, tumor vascularization and prognosis is 
not straightforward. In gastrointestinal NENs this correlation is unclear, only in pancreatic NENs it 
has been reported that VEGF expression is higher in benign and low-grade tumors. Therefore, this 
condition results to be associated to a good prognosis and prolonged survival [9, 10]. A 
comprehensive explanation for this paradox could be that in pancreatic NENs the vascular density is 
more likely a marker of differentiation than a marker of aggressiveness. FGF, PDGF and TGF-β are 
also strongly expressed in GEP-NENs [4].  
In order to study in vivo the tumor-induced angiogenesis, we have developed an innovative model 
through the xenograft of human NEN cells into Tg(fli1a:EGFP)
y1
 [11] zebrafish embryos. This 
transgenic line, expressing the enhanced green fluorescent protein (EGFP) in the endothelial cells of 
the entire vascular tree, offers the possibility to estimate the proangiogenic potential of injected 
tumor cells and to analyze the contribution of the TME to the tumor progression in a living selective 
microenvironment [12-14]. 
 
2.2 Reactive stromal cells 
Extracellular matrix is structurally constituted by interstitial matrix, which mainly includes stromal 
cells, and by basement membrane. Extracellular matrix contains soluble molecules, such as 
chemokines, matrix metalloproteinases, protease inhibitors and growth factors. An abnormal 
extracellular matrix favors tumor progression, promoting cellular transformation and metastasis 
[15]. Among different factors involved in extracellular matrix remodeling, proteoglycans play 
different roles in cancer. In GEP NENs the expression of syndecan 2 and glypican 1 proteoglycans 
has been reported to be high in well-differentiated tumors. Their levels correlated positively with 
patient survival [16]. In a recent paper, the prometastatic enzyme heparanase, a glucuronidase, 
resulted to be overexpressed in well- but not in poorly differentiated NENs [17]. 
CAFs, a population of activated fibroblasts (also known as myofibroblasts), represent the major 
non-cancer cells within the tumor stroma. They share properties with fibroblast stimulated by 
inflammation or wound healing. Indeed, they can secrete a variety of mesenchyme-specific proteins 
[18], chemokines (CXCL-8 and CXCL-12), cytokines (interleukin-6) and growth factors, including 
VEGF, TGF-β, FGF, hepatocyte growth factor and epidermal growth factor (EGF). These factors 
are involved in paracrine signaling or activate CAFs in autocrine loops. The crosstalk between 
CAFs and cancer cells is responsible for the promotion and maintaining of the activated phenotype 
of fibroblasts and, in turn, the production of soluble factors by CAFs fosters the cancer growth and 
progression, promoting the remodeling of extracellular matrix, cell proliferation and angiogenesis 
[19]. Activated fibroblasts are recruited to the tumor site miming excessive fibrosis, as a 
consequence of inflammation and aging [20]. It has been observed that NENs are often associated 
with local or distant fibrosis and that the crosstalk between NEN cells and fibroblasts has a pivotal 
role in fibrogenesis [21]. The most common examples of fibrosis are mesenteric fibrosis, associated 
with small bowel NENs in up to 50% of cases [22], and carcinoid heart disease, characterized by 
development of fibrotic endocardial plaques, that affects up to 40% of patients with carcinoid 
syndrome [23, 24]. Several factors take part in NEN-related fibrogenesis, such as serotonin, 
connective tissue growth factor, PDGF, insulin-like growth factors (IGFs), FGF and VEGF [21]. A 
strict interaction between NEN cells and fibroblasts, with a mutual induction of cell proliferation, is 
relevant for these events [4]. 
The TME exerts a significant role in every step of tumorigenesis and progression through reciprocal 
interactions and modulation of chronic inflammation [25]. It is well-known the dual role of immune 
infiltration in tumors [26]. An imbalance of the immune system may cause chronic inflammation 
with a pro-oncogenic environment, on the contrary a well-regulated adaptive immune response is 
considered anti-tumorigenic [27]. Immune surveillance can eliminate some pre-malignant lesions 
[28], but over time, tumor cells can undergo a process called immune editing [29], becoming 
resistant to the first line of defense and able to manipulate immune cells through secretion of 
chemokine and cytokines [26]. Therefore, an inflammatory response may be either pro- or anti-
tumorigenic, depending on the overall balance of inflammatory mediators and on the type of 
immune cells infiltrating the tumor. These aspects have been also reported in GEP-NENs, where 
chronic inflammation is a relevant hallmark [1]. 
Tumor-infiltrating immune cells include T and B lymphocytes, natural killer (NK) cells, 
macrophages, dendritic cells (DC) and neutrophils [30, 31]. In a contest of chronic inflammation, 
leukocytes provide directly and indirectly several factors that can promote proliferation of cancer 
and stromal cells [32], stimulate angiogenesis, facilitate cancer cell dissemination and tumor 
immune evasion [33].  
Tumor-infiltrating lymphocytes contain various proportions of T helper cells (CD4+) and cytotoxic 
T cells (CD8+). Their presence is associated with a better prognosis in a wide range of solid tumors 
[25, 30, 34]. In NENs, particularly in carcinoids of lung and midgut, tumor-infiltrating lymphocytes 
(CD4+, CD8+ and CD20+) are often found and its occurrence correlates inversely with the presence 
of metastases [35]. Also pancreatic NENs commonly showed an intratumoral infiltration with 
CD4+, CD8+ and CD3+ T cells [36]. A recent paper characterized T-cell subpopulations in both 
intra- and extra-tumoral compartments in small intestine and pancreatic NENs through a panel of T-
cell markers, comprising CD3 (general T-cell marker), CD45RO (T memory), CD8 (cytotoxic T 
cell), and FOXP3 (T regulatory cell). T-cells (CD3+, CD45RO+ and CD8+) were observed in both 
small intestine and pancreatic NENs, with a more relevant infiltration in pancreatic NENs, 
particularly in the extratumoral compartment. Levels of FOXP3 T regulatory cell infiltration were 
low in both tumors [37]. However, the expression of regulatory T cells appears to be not marginal 
in NENs, particularly in aggressive forms. These cells can stimulate metastasis formation and 
mediate the suppression of the immune system [38-40]. In another series of NENs, pancreatic 
intratumoral regulatory T cell infiltration was present in 55% of intermediate/high-grade tumors, 
whereas only in 16% of low-grade NENs [39]. Patients with midgut carcinoid showed higher levels 
of circulating regulatory T cells compared to healthy donors, particularly in patients with a high 
tumor burden [40].  
Macrophages represent a remarkable portion in tumor mass. These cells display a substantial grade 
of plasticity, with different state of activation in response to a variety of external stimuli. Indeed, 
macrophages can be polarized into type I (M1) and type II (M2) [41]. M1 macrophages exert an 
anti-tumor effect, through the production of several pro-inflammatory cytokines, chemokines, and 
effector molecules, such as interleukin-1 (IL-1), IL-12, IL-23, TNF-, CXCL10, iNOS and 
MHCI/II. In contrast, M2 macrophages promote tumor proliferation and progression, tumor 
angiogenesis, metastasis formation and immune suppression, through the expression of a wide 
spectrum of anti-inflammatory molecules, such as IL-10, TGF-β and arginase-1 [41, 42]. M2 
macrophages can also switch T-lymphocytes to regulatory T cells, allowing the suppression of 
tumor immunity [43]. Numerous studies have demonstrated in most human cancers that a high 
presence of infiltrated macrophages is linked with poor prognosis [26, 44]. In pancreatic NENs, 
tumor-associated macrophages infiltration correlates with proliferative activity, tumor grade, 
presence of liver metastases, angiogenesis and recurrence after surgery [45-47]. In addition, low 
tumor-associated macrophages, low peritumoral CD4+ cell and high intratumoral CD8+ T cell 
infiltration was associated with prolonged disease-free and/or disease-specific survival in pancreatic 
NENs [48]. 
DCs are key mediators of the adaptive and innate immune responses, therefore, these cells play a 
pivotal role in shaping the immune response. DCs are designed to present antigens and provide 
different signals, such as co-stimulatory molecules and cytokines, essential for T cell activation, to 
interact with other immune cells, including NK and B cells [49]. Tumor-infiltrating DCs are present 
in different types of solid tumors and can be associated with both a better and poor prognosis [50]. 
Besides, phenotype and amount of DCs are dynamic over time and may considerably influence 
tumor progression [49]. Although a complete characterization of DCs has never been reported in 
GEP NENs, Schott et al. described that vaccination with tumor lysate-pulsed DCs induced a clear 
antitumor effect in a patient with pancreatic neuroendocrine carcinoma [51]. Interestingly, 
Papewalis and colleagues identified a population of DCs with NK cell properties, expressing the 
CD56 NK marker [52]. Afterwards, it has been reported higher numbers of circulating  
CD14+/CD56+ monocytes in 4 patients with gastrointestinal neuroendocrine cancer compared to 
healthy controls [53]. 
NK cells are a subset of innate lymphoid cells and represent about 5–15% of the circulating blood 
mononuclear cell population. These cells are involved in the first line of defense against infection 
and cancer [54, 55]. It has been reported that NK cell activity, expressed as percentage of 
cytotoxicity in patients with gastrointestinal NENs, is affected by the type of gastrointestinal 
hormones produced and by the course of the disease with an impairment during tumor progression 
[56]. In addition, serotonin, the hormone most frequently related to carcinoid syndrome in NENs, 
stimulates migration of NK cell [57] and protects these cells against oxidatively induced functional 
inhibition and apoptosis [58]. 
 
2.3 Inflammatory mediators 
The interplay between immune cell components and tumor cells is well orchestrated and several 
molecular mediators and pathways take part in inflammation-mediated cancer and immune 
modulation. Common inflammatory mediators are cytokines, chemokines, nuclear factor kappa B 
(NFk-B), STAT3, cyclooxygenase-2 and reactive oxygen and nitrogen species. An inflammatory 
stimulus causes the recruitment and activation of different immune cells (macrophages, DCs and 
neutrophils), which release reactive oxygen and nitrogen species. The over-production of these 
oxidative agents causes genomic instability, the increase of angiogenesis and transcriptional 
activation of proto-oncogenes, concurring to inflammation-induced carcinogenesis and tumor 
metastatic potential [59].  
Chronic inflammation plays a critical role in the occurrence of GEP NENs through the network of 
different cytokines and growth factors, which modulate tumor cell growth [60], such as TNF-α, IL-
2, IL-6, IL-8, IL-1β [61-65]. Noteworthy, cytokine genes are highly polymorphic. Single nucleotide 
polymorphisms affect cytokine expression and function regulation. IL-2–330G/G genotype was 
associated to higher IL-2 serum levels and an higher risk to develop GEP NENs compared to 
healthy volunteers. Interestingly, highest IL-2 serum levels were observed in patients with 
functional NENs [61]. Similar associations have been observed between IL-6–174G/G, TNF-α-
1031C and IL-1β-511C/T genotypes, high circulating levels of corresponding cytokines and an 
increased risk to develop GEP NENs [62, 66, 67]. GEP NENs are characterized by an abundant 
production and secretion of growth factors, in particular VEGF, EGF, PDGF, IGF, FGF and TGF-β, 
which, in combination with high level of cytokines, connect chronic inflammation to 
gastrointestinal carcinogenesis [68-71].  
The pro-inflammatory mediators, produced during chronic inflammation, activate several signaling 
cascades, such as NFk-B and STAT3 pathways, that are central in the development and maintaining 
of the TME. NFk-B is a transcription factor that, following an inflammatory stimulus, translocates 
to the nucleus, where it activates transcription of target genes encoding pro-inflammatory cytokines, 
chemokines, NOS2 and cyclooxygenase-2. Moreover, NFk-B activation stimulates angiogenesis by 
VEGF secretion and makes tumor cells more resistant to necrosis and apoptosis. NFk-B is linked to 
different cellular signaling pathways. Over the last years, several reports have described Notch-
NFk-B pathway crosstalk [72]. In NENs it has been demonstrated that non-canonical Notch 
signaling impacts on tumorigenesis by the involvement of different signaling pathways, among 
them NFk-B [72, 73]. 
The signal transducer and activator of transcription, STAT3, has a relevant role in inducing and 
maintaining a pro-carcinogenic inflammatory TME. Its persistent activation in cancer cells 
promotes cell proliferation, tumor invasion and angiogenesis. Like NFk-B, STAT3 is activated by 
different factors and it can stimulate the transcription of several pro-inflammatory cytokines, 
controlling inflammation and immune evasion. In GEP NENs STAT3 has been reported to be up-
regulated and nuclear STAT3 expression correlated with metastatic status [74]. 
Other players taking part in this complex scenario, are cyclooxygenases. These are enzymes 
necessary to the production of prostaglandins from fatty acids. Prostaglandins are key mediators in 
inflammation, and in tumors can affect cell proliferation, DNA mutation rates, angiogenesis and 
promote metastasis formation [75]. Cyclooxygenase-2 expression has been detected in the vast 
majority of GEP NENs, both in functioning and non-functioning tumors [76], and its expression has 
been associated with a poor prognosis and more aggressive pathologic variables [77-79].  
Therefore, chronic inflammation promotes tumor, causing genomic instability, increasing 
angiogenesis, altering the genetic/epigenetic state and increasing cell proliferation. Several studies 
have shown that GEP NENs are closely associated with inflammatory conditions. 
 
 
3. NEN and inflammatory GEP diseases 
The gastrointestinal tract contains the highest concentration of bacteria anywhere within the human 
body. This organ is constantly exposed to materials originating from the external environment. The 
balance of the gastrointestinal microbial community is critical not only for this organ but also for 
maintenance of host health. Indeed, failure of gut homeostasis is an important factor in the 
pathogenesis and progression of systemic inflammation, which has a relevant role in the process of 
aging and several age-related disease [80, 81]. 
Throughout the whole gastroenteric tract and pancreas at least 19 types of neuroendocrine cells 
have been observed. As previously reported, these cells are not exempt from the detrimental effects 
of long-standing inflammation. Indeed, neuroendocrine cells can be overstimulated by chronic 
inflammation, leading to hyperplasia and sometimes to dysplasia, that may evolve to neoplastic 
transformation. This consequential relationship has been demonstrated in some districts of the GEP 
tract. 
 
3.1 Gastric NEN 
Gastric NENs are tumors originating from enterochromaffin-like (ECL) cells which are mainly 
localised in the gastric fundus and corpus. The main role of ECL-cells is the secretion of histamine, 
that stimulates acid secretion by parietal cells. Clinically, gastric NENs are categorized into types I, 
II, and III. Type I lesions correspond to the majority of gastric NENs and they are associated with 
chronic atrophic gastritis, either autoimmune-driven or as a consequence of Helicobacter pylori 
infection. In chronic atrophic gastritis, the destruction of the gastric parietal cells reduces the 
production of hydrochloric acid and intrinsic factor, promoting hypergastrinemia and pernicious 
anemia, respectively. The gastrin excess stimulates ECL cells proliferation and favors the 
development of type I gastric NEN [82, 83]. 
A population-based case-control study, comparing 1,138,390 cancer cases with 100,000 matched 
individuals without cancer, showed that subjects with chronic atrophic gastritis associated with 
pernicious anemia have a significantly increased risk of type I gastric NENs (odds ratio, 11.43; 95% 
CI 8.90–14.69) [84]. This tumor arises in patients with chronic atrophic gastritis in a percentage 
variable from 1 to 11%  [85-88]. 
Helicobacter pylori is a gram-negative bacterium whose outer membranes are composed by 
lipopolysaccharides. Experiments made on rat ECL cell preparation showed that Helicobacter 
pylori lipopolysaccharides stimulate histamine release, that was independent by the gastrin action, 
and potentiate gastrin-driven DNA synthesis in ECL cells [89]. 
Other alterations in the gastric microbiota could be also involved in this detrimental process. In fact, 
hypochlorhydria is able to modify the composition of the gastric microbiota by providing a different 
environment for colonization. This event could potentially increase the risk of developing a gastric 
malignancy. A recent study comparing the human gastric microbiota in different conditions, showed 
that autoimmune atrophic gastritis resulted in greater bacterial abundance and diversity compared to 
normal stomach and patients with Helicobacter pylori-induced atrophic gastritis. In both patients 
with atrophic gastritis due to autoimmune etiology or Helicobacter pylori, an over-activation of 
several pathways has been observed compared to controls. Interestingly, gastric-atrophy resulted to 
be associated with a modulation in the citric acid cycle, a biochemical pathway with a relevant role 
in gastric carcinogenesis [90].  
Therefore, autoimmune stimuli or Helicobacter pylori infection trigger an inflammatory response 
that determines parietal cell loss [91]. ECL cells are spared by this cellular destruction and induced 
to proliferate [89]. Indeed, in the setting of type A chronic atrophic corpus-fundus restricted 
gastritis, both hyperplastic and dysplastic lesions of ECL cells may be observed (figure 2), each 
bearing increased risk of tumor development [88]. It was shown that a gastric mucosa with severe 
hyperplasia (at least 6 intraglandular ECL cell chains of at least 5 cells each per mm of mucosa or at 
least 9 linear plus micronodular changes) and dysplasia (enlarged, fused or stroma dissected 
micronodules or microinfiltrative lesions) needs to be adequately followed by endoscopy and 
biopsies because of the increased neoplastic risk of these lesions [88]. 
 
3.2 Pancreatic NEN 
Chronic pancreatitis represents an independent significant risk factor for pancreatic cancer [92, 93]. 
The strength of the relationship between these two diseases has been widely reported. In a 
multicenter cohort study of 2015 cases [92] of pancreatitis, 56 cases of pancreatic cancer were 
registered during a mean follow-up of 7.4 years.  Among these, 29 cases were diagnosed 2 years 
after the diagnosis of pancreatitis. This number was higher than the expected for age, sex and the 
center. A case-control study [93] analyzed how frequent was the occurrence of pancreatitis in 2639 
patients with pancreatic cancer, compared to 7774 control subjects. The evidence was that 
pancreatitis was present in around 6% of patients with cancer and it represents a strong risk factor 
for development of pancreatic tumors. Although in most of these studies the tumor histotype was 
not specified, this association appears to be relevant for pancreatic adenocarcinoma.  
On the other hand, it is less clear the potential association between NEN and pancreatitis. In this 
setting, even hyperplastic and dysplastic lesions of endocrine cells consequent to inflammation, 
have never been clearly described. Rather, what is known is that, in the late phase of chronic 
pancreatitis, an apparent prominence of the endocrine cells is observed, probably due to the 
preferential loss of acinar tissue. This "pseudohypertrophy" may be difficult to distinguish from 
neuroendocrine microadenoma (figure 3). Therefore, data related to the incidence of cancer in this 
setting may be influenced by the potential of incorrect diagnosis of NEN.  
A case-control study including 162 sporadic pancreatic NENs and 648 controls showed that history 
of chronic pancreatitis (OR =  8.6; 95% CI, 1.4–51) and diabetes (OR =  40.1; 95%  CI, 4.8–328.9) 
resulted to be independent risk factors for the development of this tumor [94]. Although the 
association between pancreatic NENs and chronic pancreatitis has been not confirmed in other 
studies, a recent meta-analysis showed that history of diabetes mellitus was associated with an 
increased risk of sporadic pancreatic NENs (pooled adjusted odds ratio 2.74, 95% CI: 1.63-4.62) 
[95]. It is still unclear whether diabetes is a real risk factor or a secondary effect due to the 
pancreatic tumor. Furthermore, it is possible that chronic inflammation and oxidative stress may 
contribute to the pathogenesis of both diabetes and pancreatic NENs through the induction of DNA 
mutation [96]. A recent study showed that in genetically engineered transgenic mice, chronic 
inflammation in the absence of TP53 developed in all animals several subtypes of pancreatic 
cancer, including NENs [97].  
 
3.3 Small bowel and appendix NEN 
Several chronic inflammatory bowel conditions represent a potential risk factor predisposing to the 
development of small bowel NENs [98]. 
In celiac disease (CD), an immune-mediated disorder involving the small bowel, serotonin-
producing neuroendocrine cells are increased [99]. Well-oriented bioptic samples taken from 17 
patients affected by refractory CD, were compared with 84 non-healthy and 16 healthy control 
subjects. In this study the number of neuroendocrine cells was absolutely more represented in 
refractory CD. A higher expression was also observed in case of CD before gluten-free diet that 
restored to normality after [99]. This finding was indicative of a possible etiologic role of the 
immune system in the proliferative activity of these cells [100]. In addition, significantly higher 
serotonin levels have been described in patients with CD compared to healthy subjects [101]. In a 
large population-based cohort study, the standardized incidence ratio for small-intestinal cancer 
(adenocarcinomas, stromal tumors and NENs) was more than fourfold in patients with CD. 
However, the association between CD and NENs is doubtful. Indeed, in this study there are no data 
on the number of patients with NENs [102]. Despite the hyperplasia of entero-chromaffin cells has 
been demonstrated in CD, only few case reports have been published describing CD subjects with 
small bowel NENs [103-107]. 
Population-based studies [108, 109] have shown that the incidence of NENs is significantly 
increased in inflammatory bowel diseases (IBD) involving the small bowel. Among a cohort of 
20.917 patients affected by Crohn's disease in the time frame between 1978 and 2010, 23 small 
bowel adenocarcinoma and 9 NENs were observed, resulting, respectively in a 14-fold and 7-fold 
increased neoplastic risk, as compared to the general population. In both histotypes the severity of 
the surrounding inflammatory disease was moderate to severe and its distribution was extensive. 
Furthermore, while almost all adenocarcinomas arose in mucosal areas affected by Crohn's disease, 
78% of NENs developed far from them. This suggests that the development of NENs may be 
secondary to the effects of pro-inflammatory cytokines, rather than a local inflammatory effect from 
adjacent Crohn's disease. In the same study 42.872 cases of ulcerative colitis were also analyzed 
and no significantly increased risk of cancer was found among those patients [108]. 
The appendix is the third more frequent site of gastrointestinal-NENs. Appendiceal NENs are often 
diagnosed incidentally on histopathological examination of appendectomy specimens. In about two 
thirds of cases, they are found at the tip of the organ and are not the direct cause of the appendicitis 
[110]. In case of acute appendicitis, the number of enterochromaffin cells, that populate the crypt 
epithelium, and of subepithelial neuroendocrine cells is depleted [111]. Although no clear data are 
available concerning a potential association between chronic appendiceal inflammation and risk of 
NEN, the inflammation caused by other disease, such as Crohn’s disease, represents a favorable 
situation for the development of the appendiceal NEN. Indeed, it seems to occur more frequently in 
the samples from inflamed surrounding than that reported in autopsy studies [112]. 
A recent meta-analysis of observational studies provides additional evidence for a link between 
inflammation and intestinal NENs. This study reported that aspirin use was associated with a 
significant decrease in the risk of several tumors, including small intestinal NENs (RR = 0.17, 95% 
CI: 0.05–0.58) [113].  
 
3.4 Colonic and rectal NEN 
During inflammatory diseases affecting the colonic and rectal tube, as IBD, post-dysenteric colitis, 
Campylobacter enteritis and irritable bowel syndrome, an increase in number of neuroendocrine 
cells (figure 4) can be observed [114]. In all these cases, there is a disruption of the intestinal 
epithelial barrier that dysregulates innate and immune responses toward the enteric microbiota. This 
favors the release of several cytokines, that finally affect the commitment of multipotential-
secretory precursor cells and promote the differentiation of enteroendocrine precursor cells [115]. 
This phenomenon was deepened with in vitro and in vivo models of intestinal inflammation [114], 
where it was shown that PI3K/Akt signaling and autophagy are implicated in the increase of colonic 
intestinal epithelial cells expressing chromogranin. Indeed, the concomitant treatment of interferon-
γ plus TNF-α increased the number of chromogranin A-positive cells in the distal colon of colitic 
mice and this determined an increase of pAkt (Ser473) and pAkt(Thr308), an augmented 
phosphorylation of β-catenin at Ser552 [116], GSK3β at Ser9 [117] and 14-3-3ζ at Ser58 [118], 
three well-known targets of Akt, and enhanced PTEN phosphorylation. p-PTEN is the inactive 
form, that causes PI3K/Akt signaling activation in chromogranin A-positive cells. The reason why 
cytosolic chromogranin A increases in case of inflammation is not clear. It was supposed that 
entero-endocrine cells, with their capacity of antigen internalization, could represent a relevant 
sensor for the mucosa during inflammation. Similarly, in humans neuroendocrine differentiation is 
relatively common and represents an early event in the ulcerative-colitis-associated carcinogenesis, 
where chromogranin A and p53 are up-regulated [119]. 
Discordant opinions exist on whether the coexistence of IBD (both ulcerative colitis and Crohn's 
disease) and colonic and rectal NEN is only coincidental. According to some authors [120], an 
apparent high rate of incidental NENs in IBD patients could be explained only because they 
frequently undergo intestinal surgery. Indeed, adjusted for resection type, sex and age, a lower 
prevalence of NENs in IBD patients has been reported compared to non-IBD patients (diverticulitis 
or ischemic). 
Other studies reported an increased risk (up to 15 times) of intestinal NENs in IBD. While 
neuroendocrine tumors are more common in segments that are free from inflammation [121, 122], 
neuroendocrine carcinomas develop mainly in inflamed mucosa [122, 123], just like what it 
happens for non-neuroendocrine cancer. Although NENs occur in ulcerative colitis [124] as well as 
during Crohn's disease, some authors are inclined to think that the incidence is higher in Crohn's 
disease, triggered by prolonged inflammation, even in distant bowel segments [121, 125].  
 
 
4. Prognostic value of inflammatory markers in NENs 
In support of a role of inflammation in tumor development and progression, several studies 
recognized few inflammatory biomarkers as independent prognostic markers in patients with 
tumors [126]. Most of these data have been recently confirmed in NENs. Neutrophils, the most 
abundant white blood cell subset, appear to have an active role in tumorigenesis and tumor 
progression by secreting several cytokines, able to promote tumor cell proliferation, local invasion, 
angiogenesis and resistance to chemotherapy [127]. On the other hand lymphocytes play an 
important role in cell-mediated immune response activation. CD4+ T lymphocytes are involved in 
senescence and cancer immune-surveillance, detecting and eradicating precancerous and cancerous 
cells, also by activation of CD8+ T lymphocytes. Lymphocyte infiltration is common in NENs, as 
assessed by immunohistochemistry for CD3, CD4, CD8, and CD56 [39, 128]. In patients with 
intermediate-grade NENs a prominent tumor infiltration of T cells (CD3+) was associated with 
improved regression free survival, while a low level of infiltrating regulatory T cells in liver 
metastases was a predictor of prolonged survival [39]. 
Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are systemic 
inflammation markers with a prognostic value in several neoplasms. Some studies addressed the 
prognostic relevance of NLR and PLR in GEP NENs, demonstrating that these parameters could be 
useful in identifying patients with a worse outcome [129, 130]. In a retrospective study including 
172 patients with pancreatic NENs, elevated NLR and PLR were both associated with advanced 
tumor stage and high grade. In the univariate analysis, elevated NLR and PLR were both 
significantly associated with decreased overall survival and disease free survival, while in the 
multivariate analysis, the preoperative NLR, but not the PLR, was an independent risk factor. In 
detail, a preoperative NLR >2.31 was predictive of significantly worse survival in the subgroup of 
patients with stage I/II or grade 1/2 tumors. Moreover, predictive models based on both the NLR 
and conventional stratification systems, such as the WHO classification and AJCC stage, showed 
improved predictive power as compared to the stratification systems alone [131].  
Recently, increased NLR was found to be associated to advanced T stage, lymph node metastasis, 
tumor thrombus formation and advanced grade in pancreatic NENs. In addition, the recurrence-free 
survival of these patients with high NLR was significantly lower compared with those with low 
NLR [132]. Accordingly, in patients with gastric NEN, NLR was an independent prognostic factor 
for recurrence-free survival and overall survival [133].  
The gamma-glutamyltransferase (GGT) level is a biomarker of oxidative stress and correlates with 
inflammation in the extracellular tissue microenvironment. GGT can play a relevant role in cancer 
progression and biological behaviour, and is considered a significant prognostic biomarker in 
several tumors. On the other hand, lymphocytopenia, indicating a state of depressed immune 
function, could negatively affect survival of cancer patients because of a reduced host response. 
Therefore, the GGT to lymphocyte ratio index (GLRI) could represent a potentially useful 
prognostic biomarker in oncology. In a retrospective study including 125 non-functioning 
pancreatic NENs undergoing curative resection, GLRI was found to be an independent predictor of 
overall survival and disease free survival. Moreover, preoperative GLRI was associated with 
advanced tumor stage [134]. 
C reactive protein (CRP) is an acute-phase protein, produced in the liver, whose synthesis is 
triggered by secretion of IL-6 from macrophages and T cells. Any type of chronic or acute 
inflammatory process can activate acute phase response, making CRP levels a sensitive but 
unspecific marker. CRP has been shown to be an independent prognostic marker in patients with 
secreting (insulinoma, gastrinoma and other rare functioning tumours) and non-secreting sporadic 
pancreatic NENs, since it correlated with overall survival. Moreover in univariate Cox regression, 
pancreatic NEN patients with elevated CRP levels had a significantly higher hazard ratio for death 
[135]. 
Angiopoietins (Ang)-1 and -2, and the tyrosine kinase receptor Tie-2 family are involved in 
angiogenesis that in turn is known to have a key function in tumorigenesis. In addition, this system 
has a relevant role in the inflammatory processes, with a close loop relationship between 
angiogenesis and inflammation, particularly in IBD. Interaction of Ang-1 with Tie-2 promotes 
endothelial cell survival, while Ang-2 exerts a marked pro-angiogenic effect, when VEGF is 
present, and is involved in chemo-attraction of monocytes in neoplastic tissue. Monocytes 
expressing Tie-2 and recruited into inflamed or neoplastic tissues can promote angiogenesis. 
Moreover, there is a soluble form of Tie-2 that has been found increased in several conditions 
including cancer. GEP NEN patients showed enhanced serum levels of soluble form of Tie-2, Ang-
1, and Ang-2, compared to age-matched healthy controls. Soluble Tie-2 and Ang-2 levels were 
significantly higher in GEP NENs with metastases compared to those without metastases. 
Furthermore, Ang-1, Ang-2, and Tie-2 expression was found to be increased in freshly isolated 
tumor cells from GEP NEN. Interestingly, an enhanced expression and function of Tie-2 was 
detected in monocytes from GEP NEN patients. Overall these data would suggest that the Ang/Tie-
2 system is involved in the growth and dissemination of GEP NENs, also favouring the recruitment 
of Tie-2(+) monocytes to the tumor site, where they can promote inflammation and angiogenesis 
[136]. Similarly, Srirajaskanthan R et al. found Ang-2 levels to be increased in patients with well or 
moderately differentiated NENs, mostly of pancreatic, duodenal or jejunum origin, as compared to 
healthy controls, and to be significantly higher in presence of metastases as compared to non-
disseminated tumours. Moreover patients with higher Ang-2 levels (>4756  pg/ml) showed a shorter 
time to disease progression, overall suggesting a potential prognostic role for Ang-2 in patients with 
NENs [137]. 
 
 
5. Therapeutic applications with new checkpoint inhibitors 
Unravelling and understanding the mechanisms implicated in the immune response to neoplasms, 
induced by tumour-associated antigens, is crucial also in the context of NENs, for gaining new 
knowledge on tumour biology and for improving the management with the perspective of an 
immunotherapeutic approach. The therapeutic implications of the involvement of immune system in 
patients with NENs are known since the introduction of interferon-α biotherapy, which inhibits cell 
cycle progression and hormone synthesis in tumor cells, reduces neoangiogenesis, and activates 
immune cells [138]. Somatostatin receptors, which are targets widely used for the diagnosis and 
therapy of NETs [139-142], are also present in immune cells and able to mediate immune and 
inflammatory reactions [143]. Monocyte-derived cells and mature T-lymphocytes express 
somatostatin receptors -2 and -3, respectively. Human lymphoid follicle centers, thymus, and spleen 
express both receptors as well. In thymus, several evidences suggest the potential physiological role 
of somatostatin receptors in thymocytes maturation [144]. Although the effects of somatostatin 
analogues on immune system are not well defined in patients with NETs, these compounds are able 
to potentiate the cytotoxicity of interleukin-2 activated peripheral blood mononuclear cells in 
patients with medullary thyroid cancer [145].   
The occurrence of immune response to NENs is demonstrated by the frequent finding of 
lymphocyte infiltration within the tumour, as discussed in the previous paragraphs. In the view of a 
potential immunotherapy, specific tumour-associated antigens recognised by CD8+ T cells have 
been identified in patients with midgut NENs [128].  
NENs can elude immunosurveillance regardless of the immunocompetence of the host. In 
pancreatic NENs, HLA class I antigen expression was lost or reduced in most of the cases, with the 
loss of beta-2microglobulin as the most frequent alteration in HLA class I phenotype. HLA class II 
antigens seemed not to contribute to the biology of NENs, since they were not expressed in all 
investigated samples [36]. However, in another study, MHC class II expression on pancreatic tumor 
cells correlated significantly with severity and activity of intratumoral inflammation, as well as with 
the infiltration of CD4+ T lymphocytes [146].  
Anti-tumor immune responses can be impaired by regulatory T cells. Midgut carcinoid patients 
exhibited increased frequencies of circulating regulatory T cells and patients’ T cells were less 
responsive to polyclonal activation and had a decreased proliferative capacity compared to controls. 
Moreover, circulating T helper-promoting cytokines were reduced [40]. 
Programmed death 1 (PD-1), its ligands (PD-L1 and PD-L2) and cytotoxic T-lymphocyte antigen 4 
(CTLA-4) are immunosuppressive molecules with a relevant role in the host immune response to 
tumors, inhibiting T-cell activation. Lamarca A. et al. found that one third of 62 patients with well-
differentiated small intestinal NEN expressed PD-L1 in tumor or tumor-infiltrating lymphocytes 
[147]. Expression of PD-L1 was observed also in 14% of tumors and in 27% of tumor-associated 
immune cells in patients with poorly-differentiated neuroendocrine carcinomas of the digestive 
system [148]. In GEP NEN patients, PD-L1 expression was found significantly associated with a 
high-grade WHO classification (G3) but not with gender, primary site, or lymph node status. 
Moreover, G3 tumors were characterized by strong PD-L1 expression in intra/peri-tumoral 
infiltrating immune cells [149]. Likewise, in a study of 32 metastatic GEP NEN, the expression of 
PD-L1, observed in 22% of patients, was associated with higher WHO tumor grade (grade 3) and 
had both predictive and prognostic value for survival of patients [150]. In 244 GEP NENs, mostly 
of the small intestine and pancreas and predominantly G1-G2, high tumor-infiltrating lymphocytes 
(19.6%) and high PD-1 (16.1%) expression significantly correlated with shorter patient survival and 
with a higher grading. In the same study, expression of PD-L1 (8.7%) showed a trend toward a 
shorter patient survival [151]. Furthermore, Sampedro Nunez et al. found PD-1/PD-L1 expressed in 
1 to 8% of GEP NENs. In the same patients, PD-1 tumor expression was higher in metastatic 
patients, while PD-1 expression in peripheral blood monocytes was associated with tumor 
progression [152].  
Conversely, in 66 patients with GEP NEN, mostly of pancreatic origin, PD-L1 expression was 
observed in 9%, while PD-L2 was present in 50% with no association with disease stage at 
diagnosis or survival. However, they found an inverse relationship between hypoxia and 
angiogenesis biomarkers and PD ligands, as PD-L1 positive tumors had lower VEGF-A, Hif-1a and 
Carbonic Anhydrase (CaIX) expression, while PD-L2 positive tumours had lower CaIX and lower 
proportion of vascular invasion [153]. Recently, in 102 NENs of duodenum, jejunum and ileum, 
expression of PD-L1 in ≥1% and ≥50% of tumor cells was found in 39% and 14% of cases 
respectively, with an intratumor host immune response found to be apparently absent in 34% and 
intense in 21% of cases. PD-L1 expression and extent of immune infiltration were significantly 
higher in duodenal as compared with jejunal/ileal NENs.  However, neither PD-L1 expression nor 
the degree of immune infiltration showed any prognostic significance [154]. 
Antibodies targeting PD-1 (pembrolizumab, nivolumab, PDR001, JS001), PD-L1 (avelumab, 
durvalumab) or CTLA-4 (ipilimumab, tremelimumab) have been recently used in several cancers 
with promising results, and few trials are now in progress for GEP NENs (table 1). In a phase Ib 
study (KEYNOTE-028), that included patients with various advanced solid tumors, pembrolizumab 
(10 mg/kg every 2 weeks) resulted in an objective response rate of 12% out of 25 advanced PD-L1-
positive carcinoid patients and 6% out of 16 pancreatic NEN patients. None of the carcinoid and 
pancreatic NEN patients reached complete remission, whereas 60% and 88% of the patients, 
respectively, had stable disease [155]. 
Taking into consideration that, in some studies, PD-1/PD-L1 expression appears to correlate with 
higher NEN grade and with reduced survival, immunotherapy targeting this system might be 
interesting for this subgroup of tumors with a poor prognosis. Nevertheless, more knowledge about 
the composite immune landscape of these heterogeneous tumors needs to be gained in order to 
identify the subset of NEN patients most likely to benefit from immunotherapeutic approach.  
 6. Conclusions 
Several evidences suggest a relationship between neuroendocrine system and inflammation, which 
in turn can play a relevant role in tumorigenesis. Inflammatory mediators, which are produced by 
the NEN or as part of the host innate immune response, can favour angiogenesis, cancer progression 
and metastatic spread, and can promote immune editing. On the other hand, a balanced immune 
system represents a relevant step in cancer prevention through the elimination of dysplastic and 
cancer cells. Therefore, an inflammatory response may be both pro- and anti-tumorigenic. 
Although several studies reported an increased risk of GEP NENs in patients with gastrointestinal 
inflammatory diseases (chronic atrophic gastritis, chronic pancreatitis, celiac disease, Crohn’s 
disease and ulcerative colitis), most of these studies are retrospective and characterized by potential 
biases. Therefore, further studies are required to improve the level of evidence, particularly 
concerning the association between NENs and IBD. 
The modulation of the TME may represent an innovative therapeutic strategy in G3 NENs, through 
the use of checkpoint inhibitors binding to PD-1, PD-L1 or CTLA-4, thereby preventing tumors to 
evade the immune system. This aspect will be further defined with the completion of several 
ongoing clinical trials. 
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 Figure legends: 
 
Figure 1: Components of tumor microenvironment and their role in carcinogenesis and 
tumor progression through modulation of inflammation. 
 
Figure 2: Gastric hyperplastic changes of ECL cells. (a) A mild atrophic gastritis is 
shown (hematoxylin and eosin stain, 10x magnification). (b) At higher magnification (hematoxylin 
and eosin stain, 20x magnification), few cells with a clear perinuclear halo can be observed 
(arrows). (c) They are more evident on immunohistochemistry with chromogranin (20x 
magnification): neuroendocrine cells display both linear (arrow) and micronodular arrangement (*). 
 
Figure 3: Pseudohypertophy of neuroendocrine cells in chronic pancreatitis. (a) An 
example of chronic pancreatitis, where exocrine pancreatic tissue is partially replaced by fibrosis 
(hematoxylin and eosin stain, 20x magnification). (b) Langerhans islands seem to be  hyperplastic 
and more evident on immunohistochemistry with chromogranin (20x magnification).   
 
Figure 4: Inflammatory bowel diseases and NEN. (a) The rectal submucosa was occupied 
by a neuroendocrine carcinoma (positive to chromogranin) in a patient with a history of ulcerative 
colitis of at least 20 years. In the mucosa overlying the neoplastic lesion, neuroendocrine cells were 
normally represented (20x magnification). (b) Far from this lesion, an increased number of 
neuroendocrine cells was detected (40 x magnification). 
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